- Home
- LXEH vs HEPA Comparison
LXEH vs HEPA Comparison
Compare LXEH & HEPA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LXEH
- HEPA
- Stock Information
- Founded
- LXEH 2001
- HEPA 2013
- Country
- LXEH China
- HEPA United States
- Employees
- LXEH N/A
- HEPA N/A
- Industry
- LXEH Other Consumer Services
- HEPA Biotechnology: Pharmaceutical Preparations
- Sector
- LXEH Real Estate
- HEPA Health Care
- Exchange
- LXEH Nasdaq
- HEPA Nasdaq
- Market Cap
- LXEH 4.7M
- HEPA 4.1M
- IPO Year
- LXEH 2020
- HEPA N/A
- Fundamental
- Price
- LXEH $3.55
- HEPA $0.57
- Analyst Decision
- LXEH
- HEPA Hold
- Analyst Count
- LXEH 0
- HEPA 1
- Target Price
- LXEH N/A
- HEPA N/A
- AVG Volume (30 Days)
- LXEH 8.0K
- HEPA 27.6K
- Earning Date
- LXEH 09-27-2024
- HEPA 11-14-2024
- Dividend Yield
- LXEH N/A
- HEPA N/A
- EPS Growth
- LXEH N/A
- HEPA N/A
- EPS
- LXEH N/A
- HEPA N/A
- Revenue
- LXEH $5,628,870.00
- HEPA N/A
- Revenue This Year
- LXEH N/A
- HEPA N/A
- Revenue Next Year
- LXEH N/A
- HEPA N/A
- P/E Ratio
- LXEH N/A
- HEPA N/A
- Revenue Growth
- LXEH N/A
- HEPA N/A
- 52 Week Low
- LXEH $1.95
- HEPA $0.48
- 52 Week High
- LXEH $65.06
- HEPA $3.72
- Technical
- Relative Strength Index (RSI)
- LXEH 51.13
- HEPA 39.66
- Support Level
- LXEH $2.26
- HEPA $0.48
- Resistance Level
- LXEH $2.47
- HEPA $0.66
- Average True Range (ATR)
- LXEH 0.13
- HEPA 0.06
- MACD
- LXEH 0.03
- HEPA -0.01
- Stochastic Oscillator
- LXEH 50.10
- HEPA 32.88
About LXEH Lixiang Education Holding Co. Ltd.
Lixiang Education Holding Co Ltd is a private primary and secondary education service provider in Lishui City, Zhejiang Province. Its private education services primarily include primary and middle school education from grade 1 to grade 9. The company also offers high school education services at its High School Divisions.
About HEPA Hepion Pharmaceuticals Inc.
Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan-cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.